The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer.

Sponsor
Ain Shams University
Study ID
NCT07768228
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • L- carnitine — DRUG
    oral L-carnitine

Study Details

Primary outcome: To evaluate the efficacy of L-Carnitine supplementation on length and depth ulcer size Secondary outcome: To investigate the effect of L-Carnitine supplements on: 1. Vascular endothelial growth factor (VEGF) 2. Inflammatory markers TNF-a (Tumor necrosis factor alpha). 3. Hemoglobin A1C (HbA1c) And Lipid profile (cholesterol, triglycerides, high-density Lipoprotein (HDL) and low-density lipoprotein (LDL)). 4. To assess the type and likelihood of any adverse drug reaction that can be related to L-Carnitine supplementation. 5. QOL (DIABETES 39)

Key Dates

First listed
Aug 17, 2026
Start date
Sep 1, 2026
Status verified
Jul 2026
Primary completion
Jul 1, 2027
Completion
Aug 1, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    To receive oral L-carnitine plus standard care therapy
  • No Intervention: Control
    To receive only standard of care therapy

Primary Outcome Measure

Change in Diabetic Foot Ulcer area [ Time Frame: At baseline and the end of the study (after 12 weeks) ]

Central Contacts

Related Studies